Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Osimertinib
Related studies linked through entity extraction aliases.
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
- Status
- TERMINATED
- Phase
- PHASE2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
- Status
- RECRUITING
- Phase
- PHASE2
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
- Status
- RECRUITING
- Phase
- N/A
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
- Status
- RECRUITING
- Phase
- N/A
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study
- Status
- RECRUITING
- Phase
- PHASE3
Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations
- Status
- RECRUITING
- Phase
- PHASE1
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
- Status
- RECRUITING
- Phase
- NA
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neo-Bio-ADAURA: a Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib
- Status
- RECRUITING
- Phase
- PHASE2
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2